Novo Nordisk secures EU regulatory support for a 7.2 mg Wegovy pen, expanding its obesity treatment options.
Novo Nordisk (NVO) received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for a single-dose pen containing 7.2 mg of Wegovy, its obesity therapy. The endorsement marks a step toward broader EU approval for the higher-dose version.
Wegovy, a semaglutide-based treatment, has seen strong demand globally, with Novo Nordisk reporting robust sales growth in recent quarters. The 7.2 mg pen aims to simplify dosing for patients, potentially improving adherence and market penetration.
The decision follows prior approvals for lower-dose Wegovy pens in the EU and aligns with Novo Nordisk’s strategy to expand its obesity care portfolio. Final EU approval is pending, with no immediate market reaction reported.